New developments in lupus-associated antiphospholipid syndrome

Abstract

Systemic lupus erythematosus is the disease in which the antiphospholipid syndrome was first described more than 20 years ago and which is the most frequent underlying disorder in secondary antiphospholipid syndrome. With respect to pathogenic concepts and treatment, the subjects of this review, no clear distinction between primary and secondary antiphospholipid syndrome can be made.

Get full access to this article

View all access options for this article.

References

1 Miyakis S Lockshin MD Atsumi T . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295 – 306 .

2 Levine JS Branch DW Rauch J . The antiphospholipid syndrome. N Engl J Med 2002; 346: 752 – 763 .

3 Asherson RA Cervera R de Groot PG . Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530 – 534 .

4 Cervera R Piette JC Font J . Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019 – 1027 .

5 Bayraktar UD Erkan D Bucciarelli S Espinosa G Asherson R . The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007; 34: 346 – 352 .

6 McClain MT Arbuckle MR Heinlen LD . The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1226 – 1232 .

7 Erkan D Yazici Y Peterson MG Sammaritano L Lockshin MD . A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924 – 929 .

8 Bouma B de Groot PG van den Elsen JM . Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166 – 5174 .

9 Casciola-Rosen L Rosen A Petri M Schlissel M . Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996; 93: 1624 – 1629 .

10.

10 de Laat B Derksen RH . van, LM, Pennings, MT, de Groot, PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916 – 1924 .

11.

11 Hulstein JJ Lenting PJ de Laat B Derksen RH Fijnheer R de Groot PG . beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110: 1483 – 1491 .

12.

12 Girardi G . Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation. J Reprod Immunol 2005; 66: 45 – 51 .

13.

13 Salmon JE Girardi G Lockshin MD . The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 2007; 3: 140 – 147 .

14.

14 Pierangeli SS Girardi G Vega-Ostertag M Liu X Espinola RG Salmon J . Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120 – 2124 .

15.

15 Fleming SD Egan RP Chai C . Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol 2004; 173: 7055 – 7061 .

16.

16 Weitz JI Middeldorp S Geerts W Heit JA . Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program 2004; 424 – 438 .

17.

17 Finazzi G Brancaccio V Moia M . Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530 – 536 .

18.

18 Somers E Magder LS Petri M . Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531 – 2536 .

19.

19 Giron-Gonzalez JA . Garcia del, RE, Rodriguez, C, Rodriguez-Martorell, J, Serrano, A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560 – 1567 .

20.

20 Forastiero R Martinuzzo M Pombo G . A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231 – 1238 .

21.

21 Erkan D Harrison MJ Levy R . Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382 – 2391 .

22.

22 Petri M . Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191 – 193 .

23.

23 Haque S Bruce IN . Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2005; 2: 423 – 430 .

24.

24 Mok CC . Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 85 – 95 .

25.

25 Erkan D Lockshin MD . Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242 – 248 .

26.

26 Rosove MH Brewer PM . Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303 – 308 .

27.

27 Khamashta MA Cuadrado MJ Mujic F Taub NA Hunt BJ Hughes GR . The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993 – 997 .

28.

28 Crowther MA Ginsberg JS Julian J . A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133 – 1138 .

29.

29 Finazzi G Marchioli R Brancaccio V . A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848 – 853 .

30.

30 Oden A Fahlen M . Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325: 1073 – 1075 .

31.

31 Erkan D Lockshin MD . How much warfarin is enough in APS related thrombosis? Thromb Res 2004; 114: 435 – 442 .

32.

32 Kasthuri RS Roubey RAS . Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis Rheum 2007; 57: 1346 – 1347 .

33.

33 Levine SR Brey RL Tilley BC . Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576 – 584 .

34.

34 Empson M Lassere M Craig JC Scott JR . Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135 – 144 .

35.

35 Derksen RH Khamashta M Branch DW . Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 1028 – 1039 .

36.

36 Clowse ME Magder LS Witter F Petri M . Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006; 107: 293 – 299 .

37.

37 Bates SM Greer IA Hirsh J Ginsberg JS . Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 627S – 644S .